Denali Therapeutics Inc.

Developing therapies for neurodegenerative diseases that cross the blood-brain barrier.

DNLI | US

Overview

Corporate Details

ISIN(s):: US24823R1059
LEI:
Country:: United States of America
Address:: 161 OYSTER POINT BLVD., 94080 SOUTH SAN FRANCISCO
Website:: https://www.denalitherapeutics.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Denali Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapeutics to defeat neurodegenerative and lysosomal storage diseases. The company's scientific approach leverages deep expertise in genetics and the biological pathways underlying conditions such as Alzheimer's disease, Parkinson's disease, and ALS. A key focus is its portfolio of product candidates engineered to cross the blood-brain barrier, a significant challenge in treating neurological disorders. Denali advances its pipeline, which includes programs in various stages of preclinical and clinical development, through rigorous in-house research and strategic partnerships.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Denali Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Denali Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Denali Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
MESOBLAST LTD Develops off-the-shelf cellular medicines for complex inflammatory and chronic diseases.	United States of America	MESO
Metagenomi, Inc. Discovering novel gene editing tools from nature for curative genetic medicines.	United States of America	MGX
MetaVia Inc. A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.	United States of America	MTVA
Metsera, Inc. Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.	United States of America	MTSR
Mezzion Pharma Co., Ltd. Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.	South Korea	140410
MFC Co., Ltd. A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.	South Korea	432980
Milestone Pharmaceuticals Inc. Developing a self-administered nasal spray for at-home treatment of acute cardiac events.	United States of America	MIST
MIMEDX GROUP, INC. Provides placental-based biologics for advanced wound care, surgical, and burn applications.	United States of America	MDXG
Mind Medicine (MindMed) Inc. Developing psychedelic-inspired medicines and novel therapies for brain health disorders.	United States of America	MNMD
Mineralys Therapeutics, Inc. Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.	United States of America	MLYS